Oscotec Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 53

Employees

  • Stock Symbol
  • 039200

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $23.75
  • (As of Friday Closing)

Oscotec General Information

Description

Oscotec Inc is a research-oriented drug development and biotechnology company have focused on developing synthetic new drugs for diseases such as arthritis and anticancers since its inception. The firm has established a differentiated business model by commercializing various research products and accumulating knowledge obtained during the drug development process into functional materials, related products, and bone graft materials. Based on its business model, its core businesses are: 1) New drug development (synthetic new drugs), 2) Functional materials and related products, and 3) Dental bone graft materials.

Contact Information

Website
www.oscotec.com
Formerly Known As
Oscotec Co., Ltd
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 9th Floor, Building A, Korea Bio-Park
  • 700 Daewangpangyo-ro, Bundang-gu
  • Seongnam-si, Gyeonggi 13488
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 9th Floor, Building A, Korea Bio-Park
  • 700 Daewangpangyo-ro, Bundang-gu
  • Seongnam-si, Gyeonggi 13488
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oscotec Stock Performance

As of 20-Nov-2026, Oscotec’s stock price is $23.75. Its current market cap is $909M with 38.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.75 $24.50 $18.22 - $44.91 $909M 38.3M 122K $1.69

Oscotec Financials Summary

As of 30-Jun-2026, Oscotec has a trailing 12-month revenue of $99M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 809,401 1,139,675 569,713 602,451
Revenue 99,350 70,154 24,924 3,787
EBITDA 67,697 37,079 (1,541) (26,604)
Net Income 64,814 36,780 642 (18,570)
Total Assets 173,155 159,619 115,941 102,879
Total Debt 11,542 10,846 9,380 4,929
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oscotec Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oscotec‘s full profile, request access.

Request a free trial

Oscotec Patents

Oscotec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260200907-A1 Crystalline forms of spleen tyrosine kinase inhibitor ski-o-703 Pending 06-Jan-2025
WO-2026148272-A1 Crystalline forms of spleen tyrosine kinase inhibitor ski-o-703 Pending 06-Jan-2025
WO-2024123052-A1 Fusion comprising anti-tau antibody and peptide and use thereof Inactive 08-Dec-2022
WO-2020159117-A1 Oral solid formulation containing pyridopyridine-based hydrochloride and preparation method therefor Inactive 01-Feb-2019
AU-2019325764-A1 Crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido(4,3-d)pyrimidin-5(6h)-one hydrochloride and method for preparing same Active 23-Aug-2018 C07D471/04
To view Oscotec’s complete patent history, request access »

Oscotec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oscotec Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oscotec‘s full profile, request access.

Request a free trial

Oscotec Investments (1)

Oscotec’s most recent deal was a Corporate Asset Purchase with Serin Bioscience (371.9033257 SM Land and 1,956.03 SM Building in Seongnam, South Korea) for . The deal was made on 21-Jul-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Serin Bioscience (371.9033257 SM Land and 1,956.03 SM Building in Seongnam, South Korea) 21-Jul-2021 Corporate Asset Purchase Buildings and Property
To view Oscotec’s complete investments history, request access »

Oscotec ESG

Risk Overview

Risk Rating

Updated November, 08, 2026

42.62 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Oscotec’s complete esg history, request access »

Oscotec Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Genosco Billerica, MA 2000

Oscotec FAQs

  • When was Oscotec founded?

    Oscotec was founded in 1998.

  • Where is Oscotec headquartered?

    Oscotec is headquartered in Seongnam-si, South Korea.

  • What is the size of Oscotec?

    Oscotec has 53 total employees.

  • What industry is Oscotec in?

    Oscotec’s primary industry is Drug Discovery.

  • Is Oscotec a private or public company?

    Oscotec is a Public company.

  • What is Oscotec’s stock symbol?

    The ticker symbol for Oscotec is 039200.

  • What is the current stock price of Oscotec?

    As of 20-Nov-2026 the stock price of Oscotec is $23.75.

  • What is the current market cap of Oscotec?

    The current market capitalization of Oscotec is $909M.

  • What is Oscotec’s current revenue?

    The trailing twelve month revenue for Oscotec is $99M.

  • What is Oscotec’s annual earnings per share (EPS)?

    Oscotec’s EPS for 12 months was $1.69.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process